CTLA4 and melanoma: Augmented antigenicity enhanced infiltration of T cells carrying corresponding TCRs, sensitizing treatment-resistant B16F10 cells to in vivo PD-1 and CTLA-4 checkpoint blockade (however, these effects have only been tested in GVAX melanoma cells expressing GM-CSF [142]).